You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Empagliflozin

Showing 26 - 50 of 469
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics Trial (Empagliflozin,

Not yet recruiting
  • Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
  • (no location specified)
Jan 22, 2023

Type 2 Diabetes, Type 1 Diabetes Trial in San Antonio (Empagliflozin 25 MG, Placebo)

Not yet recruiting
  • Type 2 Diabetes
  • Type 1 Diabetes
  • Empagliflozin 25 MG
  • Placebo
  • San Antonio, Texas
    Texas Diabetes Institute/UH
Jul 31, 2023

Metabolic Syndrome Trial in Bydgoszcz (Empagliflozin 20 mg, Empagliflozin 10 mg)

Recruiting
  • Metabolic Syndrome
  • Empagliflozin 20 mg
  • Empagliflozin 10 mg
  • Bydgoszcz, Cuiavian-Pomeranian, Poland
    Cardiology Department, Dr. A. Jurasz University Hospital
Jun 13, 2023

Ulcerative Colitis Trial (Empagliflozin, conventional treatment)

Not yet recruiting
  • Ulcerative Colitis
  • Empagliflozin
  • conventional treatment
  • (no location specified)
Nov 9, 2022

End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis Trial (Empagliflozin, Placebo)

Not yet recruiting
  • End-stage Kidney Disease
  • +7 more
  • Empagliflozin
  • Placebo
  • (no location specified)
Jan 9, 2023

T2DM Trial (Chiglitazar, Empagliflozin, Atorvastatin)

Not yet recruiting
  • T2DM
  • (no location specified)
Dec 27, 2022

End Stage Renal Disease Trial in Boston, New York (Empagliflozin 10 MG, Placebo)

Not yet recruiting
  • End Stage Renal Disease
  • Empagliflozin 10 MG
  • Placebo
  • Boston, Massachusetts
  • +1 more
Mar 15, 2023

Heart Failure With Preserved Ejection Fraction, Microvascular Dysfunction Trial in Maastricht (Participants receive 10mg

Recruiting
  • Heart Failure With Preserved Ejection Fraction
  • Microvascular Dysfunction
  • Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment
  • Maastricht, Limburg, Netherlands
    Maastricht University Hospital
Sep 13, 2023

Diabetes, Type 2 Trial (Semaglutide, Empagliflozin)

Withdrawn
  • Diabetes Mellitus, Type 2
  • (no location specified)
Nov 11, 2022

Metabolic-associated Fatty Liver Disease, Type 2 Diabetes Trial (Empagliflozin, Dulaglutide, Empagliflozin and Dulaglutide)

Not yet recruiting
  • Metabolic-associated Fatty Liver Disease
  • Type 2 Diabetes
  • Empagliflozin
  • +2 more
  • (no location specified)
Oct 1, 2022

Idiopathic Pulmonary Arterial Hypertension Trial (Empagliflozin 10 MG)

Not yet recruiting
  • Idiopathic Pulmonary Arterial Hypertension
  • Empagliflozin 10 MG
  • (no location specified)
Aug 4, 2022

Heart Failure Trial in Lausanne, London (Dapagliflozin tablet, Empagliflozin Tablets)

Not yet recruiting
  • Heart Failure
  • Dapagliflozin tablet
  • Empagliflozin Tablets
  • Lausanne, VD, Switzerland
  • +2 more
Aug 24, 2023

Cystic Fibrosis-related Diabetes, Cystic Fibrosis Trial in Minneapolis (Empagliflozin, Placebo Control)

Not yet recruiting
  • Cystic Fibrosis-related Diabetes
  • Cystic Fibrosis
  • Empagliflozin
  • Placebo Control
  • Minneapolis, Minnesota
    University of Minnesota
Nov 20, 2023

Non Alcoholic Steatohepatitis Trial in Tanta (Pioglitazone 30mg, Empagliflozin 10 MG)

Not yet recruiting
  • Non Alcoholic Steatohepatitis
  • Pioglitazone 30mg
  • Empagliflozin 10 MG
  • Tanta, Gharbiya, Egypt
    Tanta University
Nov 2, 2022

Acute Heart Failure Trial in Shatin (Empagliflozin 10 MG)

Recruiting
  • Acute Heart Failure
  • Empagliflozin 10 MG
  • Shatin, Hong Kong
    The Chinese University of Hong Kong
Oct 2, 2022

Novel Antidiabetic Medications and Their Effect on Liver

Completed
  • Non-Alcoholic Fatty Liver Disease
  • Liver Steatosis
  • Empagliflozin
  • +2 more
  • Athens, Attiki, Greece
    "Hippocration" General Hospital of Athens
Jul 13, 2023

Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction Trial

Not yet recruiting
  • Heart Failure
  • +2 more
  • Empagliflozin 10 MG
  • (no location specified)
Oct 26, 2022

Cardiogenic Shock Trial in France (Empagliflozin 10 MG)

Not yet recruiting
  • Cardiogenic Shock
  • Empagliflozin 10 MG
  • Ars-Laquenexy, France
  • +6 more
May 24, 2023

PreDiabetes, Prediabetic State, Overweight and Obesity Trial in Corvallis (Empagliflozin, Multivitamin-Placebo)

Recruiting
  • PreDiabetes
  • +2 more
  • Empagliflozin
  • Multivitamin-Placebo
  • Corvallis, Oregon
    Oregon State University
Jul 19, 2022

Type 2 Diabetes, Cardiovascular Risk Factor Trial in Catanzaro (Empagliflozin 10 MG, Glimepiride 2 mg)

Completed
  • Type 2 Diabetes
  • Cardiovascular Risk Factor
  • Empagliflozin 10 MG
  • Glimepiride 2 mg
  • Catanzaro, Italy
    Universital Hospital Mater Domini
Jan 14, 2023

Ascites Hepatic Trial in Alexandria (Empagliflozin 10 MG, Diuretics)

Recruiting
  • Ascites Hepatic
  • Alexandria, Egypt
    Alexandria University
Jun 18, 2022

MDD Trial in New York (Empagliflozin)

Not yet recruiting
  • Major Depressive Disorder
  • Empagliflozin
  • New York, New York
    NYU Langone Health
Feb 24, 2023

Diabetes, Type 2 Trial (Empagliflozin 25 MG, INS)

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Empagliflozin 25 MG
  • INS
  • (no location specified)
Jul 19, 2022

Dumping Syndrome, Hypoglycemia, Reactive Trial in Bern (Empagliflozin 25 MG, Placebo)

Completed
  • Dumping Syndrome
  • Hypoglycemia, Reactive
  • Empagliflozin 25 MG
  • Placebo
  • Bern, Canton Of Bern, Switzerland
    Department of Diabetes, Endocrinology, Nutritional Medicine and
Aug 18, 2022

Polycystic Kidney, Autosomal Dominant Trial in Aurora (Empagliflozin, Placebo)

Not yet recruiting
  • Polycystic Kidney, Autosomal Dominant
  • Empagliflozin
  • Placebo
  • Aurora, Colorado
    University of Coloardo Anschutz Medical Campus
Aug 18, 2022